AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (278.5 KB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review Article | Open Access

Optogenetics to restore neural circuit function in Parkinson’s disease

Hyung Ho YoonJoongkee MinSang Ryong Jeon
Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea
Show Author Information

Abstract

Deep brain stimulation surgery has been performed in various movement disorders and psychiatric diseases. However, electrical stimulation may unexpectedly affect other types of adjacent neurons outside of the target area. Recently, optogenetics has provided the opportunity to modulate specific target neurons. Since this novel technique can individually control specific neurons in freely moving animals, it could be proposed to restore neural circuit function to related diseases, such as affective disorders, Huntington’s disease (HD), and Parkinson’s disease (PD). Herein, we discuss how optogenetics works as a treatment for Parkinson’s disease and other neural circuit dysfunctions.

References

[1]
Hague S, Klaffke S, Bandmann O. Neurodegenerative disorders: Parkinson’s disease and Huntington’s disease. Journal of Neurology, Neurosurgery & Psychiatry. 2005, 76(8):1058-1063.
[2]
Hedlund E, Perlmann T. Neuronal cell replacement in Parkinson’s disease. J Intern Med. Oct 2009, 266(4):358-371.
[3]
Fraix V, Pollak P, Van Blercom N, et al. Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson’s disease. Neurology. 2000, 55(12):1921-1923.
[4]
Follett KA, Weaver FM, Stern M, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med. 2010, 362(22):2077-2091.
[5]
Aravanis AM, Wang LP, Zhang F, et al. An optical neural interface: in vivo control of rodent motor cortex with integrated fiberoptic and optogenetic technology. Journal of neural engineering. 2007, 4(3):S143-156.
[6]
Larson PS. Deep brain stimulation for movement disorders. Neurotherapeutics. 2014, 11(3):465-474.
[7]
Yizhar O, Fenno LE, Davidson TJ, et al. Optogenetics in neural systems. Neuron. 2011, 71(1):9-34.
[8]
Deisseroth K. Optogenetics. Nature methods. 2011, 8(1):26-29.
[9]
Gradinaru V, Thompson KR, Zhang F, et al. Targeting and readout strategies for fast optical neural control in vitro and in vivo. The Journal of Neuroscience. 2007, 27(52):14231-14238.
[10]
Boyden ES, Zhang F, Bamberg E, et al. Millisecond- timescale, genetically targeted optical control of neural activity. Nature neuroscience. 2005, 8(9):1263-1268.
[11]
Monahan PE, Jooss K, Sands MS. Safety of adeno-associated virus gene therapy vectors: a current evaluation. Expert Opin Drug Saf. 2002, 1(1):79-91.
[12]
Connolly JB. Lentiviruses in gene therapy clinical research. Gene therapy. 2002, 9(24):1730-1734.
[13]
Kato T, Kasahara T, Kubota-Sakashita M, et al. Animal models of recurrent or bipolar depression. Neuroscience. 2016, 321:189-196.
[14]
Paille V, Henry V, Lescaudron L, et al. Rat model of Parkinson’s disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias. Mov Disord. 2007, 22(4):533-539.
[15]
Yoon HH, Park JH, Kim YH, et al. Optogenetic Inactivation of the Subthalamic Nucleus Improves Forelimb Akinesia in a Rat Model of Parkinson Disease. Neurosurgery. 2014, 74(5):533-541.
[16]
Schallert T, Fleming SM, Leasure JL, et al. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology. 2000, 39(5):777-787.
[17]
Zrinzo L, Yoshida F, Hariz MI, et al. Clinical safety of brain magnetic resonance imaging with implanted deep brain stimulation hardware: Large case series and review of the literature. World neurosurgery. 2011, 76(1–2):164-172.
[18]
Aristieta A, Azkona G, Sagarduy A, et al. The role of the subthalamic nucleus in L-DOPA induced dyskinesia in 6-hydroxydopamine lesioned rats. PloS one. 2012, 7(8):e42652.
[19]
Wichmann T, Dostrovsky JO. Pathological basal ganglia activity in movement disorders. Neuroscience. 2011, 198:232-244.
[20]
Sgambato-Faure V, Cenci MA. Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease. Progress in neurobiology. 2012, 96(1):69-86.
[21]
Yoon HH, Min J, Hwang E, et al. Optogenetic inhibition of the subthalamic nucleus reduces levodopa-induced dyskinesias in a rat model of Parkinson's disease. Stereotact Funct Neurosurg. 2016, 94(1):41-53.
[22]
Zhou L, Liu MZ, Li Q, et al. Organization of functional long-range circuits controlling the activity of serotonergic neurons in the dorsal raphe nucleus. Cell Rep. 2017, 20(8):1991-1993.
Journal of Neurorestoratology
Pages 88-92
Cite this article:
Yoon HH, Min J, Jeon SR. Optogenetics to restore neural circuit function in Parkinson’s disease. Journal of Neurorestoratology, 2018, 6(1): 88-92. https://doi.org/10.26599/JNR.2018.9040007

351

Views

17

Downloads

6

Crossref

6

Web of Science

0

Scopus

Altmetrics

Received: 09 July 2018
Accepted: 11 September 2018
Published: 09 November 2018
© The author(s) 2018

© The authors 2018. This article is published with open access at http://jnr.tsinghuajournals.com

Return